1 4179 171 MEN WHO INJECT OPIOIDS EXHIBIT ALTERED TRNA-GLY-GCC ISOFORMS IN SEMEN. IN ADDITION TO THEIR ROLE IN PROTEIN TRANSLATION, TRNAS CAN BE CLEAVED INTO SHORTER, BIOLOGICALLY ACTIVE FRAGMENTS CALLED TRNA FRAGMENTS (TRFS). SPECIFIC TRFS FROM SPERMATOCYTES CAN PROPAGATE METABOLIC DISORDERS IN SECOND GENERATIONS OF MICE. THUS, TRFS IN GERMLINE CELLS ARE A MECHANISM OF EPIGENETIC INHERITANCE. IT HAS ALSO BEEN SHOWN THAT STRESS AND TOXINS CAN CAUSE ALTERATIONS IN TRF PATTERNS. WE WERE THEREFORE INTERESTED IN WHETHER INJECTING ILLICIT DRUGS, A MAJOR STRESSOR, IMPACTS TRFS IN GERMLINE CELLS. WE SEQUENCED RNA FROM SPERMATOCYTES AND FROM SEMEN-DERIVED EXOSOMES FROM PEOPLE WHO INJECT ILLICIT DRUGS (PWID) AND FROM NON-DRUG USING CONTROLS, BOTH GROUPS OF UNKNOWN FERTILITY STATUS. ALL PWID INJECTED OPIOIDS DAILY, BUT MOST ALSO USED OTHER ILLICIT DRUGS. THE TRF CLEAVAGE PRODUCTS FROM GLY-GCC TRNA WERE MARKEDLY DIFFERENT BETWEEN SPERMATOCYTES FROM PWID COMPARED TO CONTROLS. OVER 90% OF READS IN CONTROLS MAPPED TO SHORTER GLY-GCC TRFS, WHILE IN PWID ONLY 45% DID. IN CONTRAST, ONLY 4.1% OF READS IN CONTROLS MAPPED TO A LONGER TRFS VERSUS 45.6% IN PWID. THE LONG/SHORT TRF RATIO WAS SIGNIFICANTLY HIGHER IN PWID THAN CONTROLS (0.23 VERSUS 0.16, P = 0.0128). WE ALSO REPORT DIFFERENTIAL EXPRESSION OF A GROUP OF SMALL NUCLEOLAR RNAS (SNORNAS) IN SEMEN-DERIVED EXOSOMES, INCLUDING, AMONG OTHERS, ACA14A, U19, AND U3-3. THUS, PWID EXHIBITED AN ALTERED CLEAVAGE PATTERN OF TRNA-GLY-GCC IN SPERMATOCYTES AND AN ALTERED CARGO OF SNORNAS IN SEMEN-DERIVED EXOSOMES. PARTICIPANTS WERE NOT EXCLUSIVELY USING OPIOIDS AND WERE NOT MATCHED WITH CONTROLS IN TERMS OF DIET, CHRONIC DISEASE, OR OTHER STRESSORS, SO OUR FINDING ARE NOT CONCLUSIVELY LINKED TO OPIOID USE. HOWEVER, ALL INDIVIDUALS IN THE PWID GROUP DID INJECT HEROIN DAILY. OUR STUDY INDICATES A POTENTIAL FOR OPIOID INJECTION AND/OR ITS ASSOCIATED MULTI-DRUG USE HABITS AND LIFESTYLE CHANGES TO INFLUENCE EPIGENETIC INHERITANCE. 2023 2 2580 34 EPIGENETICS OF MICRO-OPIOID RECEPTORS: INTERSECTION WITH HIV-1 INFECTION OF THE CENTRAL NERVOUS SYSTEM. THE ABUSE OF INTRAVENOUS DRUGS, SUCH AS HEROIN, HAS BECOME A MAJOR PUBLIC HEALTH CONCERN DUE TO THE INCREASED RISK OF HIV-1 INFECTION. OPIOIDS SUCH AS HEROIN WERE ORIGINALLY IDENTIFIED AND SUBSEQUENTLY ABUSED FOR THEIR ANALGESIC EFFECTS. HOWEVER, MANY INVESTIGATIONS HAVE FOUND ADDITIONAL EFFECTS OF OPIOIDS, INCLUDING REGULATION OF THE IMMUNE SYSTEM. AS SUCH, CHRONIC OPIOID ABUSE HAS BEEN SHOWN TO PROMOTE HIV-1 PATHOGENESIS AND FACILITATE HIV-1-ASSOCIATED NEUROCOGNITIVE DYSFUNCTION. CLINICAL OPIOIDS, SUCH AS MORPHINE AND METHADONE, AS WELL AS ILLICIT OPIOIDS, SUCH AS HEROIN, EXERT THEIR EFFECTS PRIMARILY THROUGH INTERACTIONS WITH THE MICRO-OPIOID RECEPTOR (MOR). HOWEVER, THE MECHANISMS BY WHICH OPIOIDS ENHANCE NEUROCOGNITIVE DYSFUNCTION THROUGH MOR-MEDIATED SIGNALING PATHWAYS ARE NOT COMPLETELY UNDERSTOOD. NEW FINDINGS IN THE REGULATION OF MOR EXPRESSION, PARTICULARLY EPIGENETIC AND TRANSCRIPTIONAL REGULATION AS WELL AS ALTERNATIVE SPLICING, SHEDS NEW INSIGHTS INTO POSSIBLE MECHANISMS OF HIV-1 AND OPIATE SYNERGY. IN THIS REVIEW, WE IDENTIFY MECHANISMS REGULATING MOR EXPRESSION AND PROPOSE NOVEL MECHANISMS BY WHICH OPIOIDS AND HIV-1 MAY MODULATE THIS REGULATION. ADDITIONALLY, WE SUGGEST THAT DIFFERENTIAL REGULATION OF NEWLY IDENTIFIED MOR ISOFORMS BY OPIOIDS AND HIV-1 HAS FUNCTIONAL CONSEQUENCE IN ENHANCING HIV-1 NEUROCOGNITIVE DYSFUNCTION. 2012 3 6722 24 VITAMIN D RECEPTOR AND EPIGENETICS IN HIV INFECTION AND DRUG ABUSE. ILLICIT DRUG ABUSE IS HIGHLY PREVALENT AND SERVES AS A POWERFUL CO-FACTOR FOR HIV EXACERBATION. EPIGENETIC ALTERATIONS IN DRUG ABUSE AND HIV INFECTION DETERMINE EXPRESSION OF SEVERAL CRITICAL GENES SUCH AS VITAMIN D RECEPTOR (VDR), WHICH PARTICIPATES IN PROLIFERATION, DIFFERENTIATION, CELL DEATH UNDER BOTH PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS. ON THAT ACCOUNT, ACTIVE VITAMIN D, THE LIGAND OF VDR, IS USED AS AN ADJUVANT THERAPY TO CONTROL INFECTION, SLOW DOWN PROGRESSION OF CHRONIC KIDNEY DISEASES, AND CANCER CHEMOTHERAPY. INTERESTINGLY, VITAMIN D MAY NOT BE ABLE TO AUGMENT VDR EXPRESSION OPTIMALLY IN SEVERAL INSTANCES WHERE EPIGENETIC CONTRIBUTES TO DOWN REGULATION OF VDR; HOWEVER, REVERSAL OF EPIGENETIC CORRUPTION EITHER BY DEMETHYLATING AGENTS (DACS) OR HISTONE DEACETYLASE (HDAC) INHIBITORS WOULD BE ABLE TO MAXIMIZE EXPRESSION OF VDR IN THESE INSTANCES. 2015 4 4441 42 MOLECULAR GENETICS OF COCAINE USE DISORDERS IN HUMANS. DRUG ADDICTION, ONE OF THE MAJOR HEALTH PROBLEMS WORLDWIDE, IS CHARACTERIZED BY THE LOSS OF CONTROL IN DRUG INTAKE, CRAVING, AND WITHDRAWAL. AT THE INDIVIDUAL LEVEL, DRUGS OF ABUSE PRODUCE SERIOUS CONSEQUENCES ON HEALTH AND HAVE A NEGATIVE IMPACT ON THE FAMILY ENVIRONMENT AND ON INTERPERSONAL AND WORK RELATIONSHIPS. AT A WIDER SCALE, THEY HAVE SIGNIFICANT SOCIO-ECONOMIC AND PUBLIC HEALTH CONSEQUENCES AND THEY CAUSE DELINQUENCY AND CITIZEN INSECURITY. COCAINE, A PSYCHOSTIMULANT SUBSTANCE, IS ONE OF THE MOST USED ILLICIT DRUGS, ESPECIALLY IN AMERICA, WESTERN EUROPE, AND AUSTRALIA. COCAINE USE DISORDERS (CUD) ARE COMPLEX MULTIFACTORIAL CONDITIONS DRIVEN BY BOTH GENETIC AND ENVIRONMENTAL INFLUENCES. IMPORTANTLY, NOT ALL PEOPLE WHO USE COCAINE DEVELOP CUD, AND THIS IS DUE, AT LEAST IN PART, TO BIOLOGICAL FACTORS THAT ARE ENCODED IN THE GENOME OF INDIVIDUALS. ACUTE AND REPEATED USE OF COCAINE INDUCES EPIGENETIC AND GENE EXPRESSION CHANGES RESPONSIBLE FOR THE NEURONAL ADAPTATIONS AND THE REMODELING OF BRAIN CIRCUITS THAT LEAD TO THE TRANSITION FROM USE TO ABUSE OR DEPENDENCE. THE PURPOSE OF THIS REVIEW IS TO DELINEATE SUCH FACTORS, WHICH SHOULD EVENTUALLY HELP TO UNDERSTAND THE INTER-INDIVIDUAL VARIABILITY IN THE SUSCEPTIBILITY TO COCAINE ADDICTION. HERITABILITY ESTIMATES FOR CUD ARE HIGH AND GENETIC RISK FACTORS FOR COCAINE ADDICTION HAVE BEEN INVESTIGATED BY CANDIDATE GENE ASSOCIATION STUDIES (CGAS) AND GENOME-WIDE ASSOCIATION STUDIES (GWAS), REVIEWED HERE. ALSO, THE HIGH COMORBIDITY THAT EXISTS BETWEEN CUD AND SEVERAL OTHER PSYCHIATRIC DISORDERS IS WELL KNOWN AND INCLUDES PHENOTYPES LIKE SCHIZOPHRENIA, AGGRESSION, ANTISOCIAL OR RISK-TAKING BEHAVIORS. SUCH COMORBIDITIES ARE ASSOCIATED WITH A WORSE LIFETIME TRAJECTORY, AND HERE WE REPORT SHARED GENETIC FACTORS THAT MAY CONTRIBUTE TO THEM. GENE EXPRESSION CHANGES AND EPIGENETIC MODIFICATIONS INDUCED BY COCAINE USE AND CHRONIC ABUSE IN HUMANS ARE ADDRESSED BY REVIEWING TRANSCRIPTOMIC STUDIES PERFORMED ON NEURONAL CELLS AND ON POSTMORTEM BRAINS. WE REPORT SOME GENES WHICH EXPRESSION IS ALTERED BY COCAINE THAT ALSO BEAR GENETIC RISK VARIANTS FOR THE DISORDER. FINALLY, WE HAVE A GLANCE TO THE PHARMACOGENETICS OF CUD TREATMENTS, STILL IN EARLY STAGES. A BETTER UNDERSTANDING OF THE GENETIC UNDERPINNINGS OF CUD WILL FOSTER THE SEARCH OF EFFECTIVE TREATMENTS AND HELP TO MOVE FORWARD TO PERSONALIZED MEDICINE. 2022 5 2573 25 EPIGENETICS OF DRUG ABUSE: PREDISPOSITION OR RESPONSE. DRUG ADDICTION CONTINUES TO BE A SERIOUS MEDICAL AND SOCIAL PROBLEM. VULNERABILITY TO DEVELOP AN ADDICTION TO DRUGS IS DEPENDENT ON GENETIC, ENVIRONMENTAL, SOCIAL AND BIOLOGICAL FACTORS. IN PARTICULAR, THE INTERACTIONS OF ENVIRONMENTAL AND GENETIC FACTORS INDICATE THE SIGNIFICANCE OF EPIGENETIC MECHANISMS, WHICH HAVE BEEN FOUND TO OCCUR IN RESPONSE TO ILLICIT DRUG USE OR AS UNDERLYING FACTORS IN CHRONIC SUBSTANCE ABUSE AND RELAPSE. EPIGENETICS IS DEFINED AS THE HERITABLE AND POSSIBLY REVERSIBLE MODIFICATIONS IN GENE EXPRESSION THAT DO NOT INVOLVE ALTERATIONS IN THE DNA SEQUENCE. THIS REVIEW DISCUSSES THE VARIOUS TYPES OF EPIGENETIC MODIFICATIONS AND THEIR RELEVANCE TO DRUG ADDICTION TO ELUCIDATE WHETHER EPIGENETICS IS A PREDISPOSING FACTOR, OR A RESPONSE TO, DEVELOPING AN ADDICTION TO DRUGS OF ABUSE. 2012 6 4418 33 MOLECULAR AND EPIGENETIC ASPECTS OF OPIOID RECEPTORS IN DRUG ADDICTION AND PAIN MANAGEMENT IN SPORT. OPIOIDS ARE SUBSTANCES DERIVED FROM OPIUM (NATURAL OPIOIDS). IN ITS RAW STATE, OPIUM IS A GUMMY LATEX EXTRACTED FROM PAPAVER SOMNIFERUM. THE USE OF OPIOIDS AND THEIR NEGATIVE HEALTH CONSEQUENCES AMONG PEOPLE WHO USE DRUGS HAVE BEEN STUDIED. TODAY, OPIOIDS ARE STILL THE MOST COMMONLY USED AND EFFECTIVE ANALGESIC TREATMENTS FOR SEVERE PAIN, BUT THEIR USE AND ABUSE CAUSES DETRIMENTAL SIDE EFFECTS FOR HEALTH, INCLUDING ADDICTION, THUS IMPACTING THE USER'S QUALITY OF LIFE AND CAUSING OVERDOSE. THE MESOCORTICOLIMBIC DOPAMINERGIC CIRCUITRY REPRESENTS THE BRAIN CIRCUIT MEDIATING BOTH NATURAL REWARDS AND THE REWARDING ASPECTS OF NEARLY ALL DRUGS OF ABUSE, INCLUDING OPIOIDS. HENCE, UNDERSTANDING HOW OPIOIDS AFFECT THE FUNCTION OF DOPAMINERGIC CIRCUITRY MAY BE USEFUL FOR BETTER KNOWLEDGE OF THE PROCESS AND TO DEVELOP EFFECTIVE THERAPEUTIC STRATEGIES IN ADDICTION. THE AIM OF THIS REVIEW WAS TO SUMMARIZE THE MAIN FEATURES OF OPIOIDS AND OPIOID RECEPTORS AND FOCUS ON THE MOLECULAR AND UPCOMING EPIGENETIC MECHANISMS LEADING TO OPIOID ADDICTION. SINCE SYNTHETIC OPIOIDS CAN BE EFFECTIVE FOR PAIN MANAGEMENT, THEIR ABILITY TO INDUCE ADDICTION IN ATHLETES, WITH THE RISK OF INCURRING DOPING, IS ALSO DISCUSSED. 2023 7 4846 23 OPIATE ADDICTION AND COCAINE ADDICTION: UNDERLYING MOLECULAR NEUROBIOLOGY AND GENETICS. ADDICTIVE DISEASES, INCLUDING ADDICTION TO HEROIN, PRESCRIPTION OPIOIDS, OR COCAINE, POSE MASSIVE PERSONAL AND PUBLIC HEALTH COSTS. ADDICTIONS ARE CHRONIC RELAPSING DISEASES OF THE BRAIN CAUSED BY DRUG-INDUCED DIRECT EFFECTS AND PERSISTING NEUROADAPTATIONS AT THE EPIGENETIC, MRNA, NEUROPEPTIDE, NEUROTRANSMITTER, OR PROTEIN LEVELS. THESE NEUROADAPTATIONS, WHICH CAN BE SPECIFIC TO DRUG TYPE, AND THEIR RESULTANT BEHAVIORS ARE MODIFIED BY VARIOUS INTERNAL AND EXTERNAL ENVIRONMENTAL FACTORS, INCLUDING STRESS RESPONSIVITY, ADDICT MINDSET, AND SOCIAL SETTING. SPECIFIC GENE VARIANTS, INCLUDING VARIANTS ENCODING PHARMACOLOGICAL TARGET PROTEINS OR GENES MEDIATING NEUROADAPTATIONS, ALSO MODIFY VULNERABILITY AT PARTICULAR STAGES OF ADDICTION. GREATER UNDERSTANDING OF THESE INTERACTING FACTORS THROUGH LABORATORY-BASED AND TRANSLATIONAL STUDIES HAVE THE POTENTIAL TO OPTIMIZE EARLY INTERVENTIONS FOR THE THERAPY OF CHRONIC ADDICTIVE DISEASES AND TO REDUCE THE BURDEN OF RELAPSE. HERE, WE REVIEW THE MOLECULAR NEUROBIOLOGY AND GENETICS OF OPIATE ADDICTION, INCLUDING HEROIN AND PRESCRIPTION OPIOIDS, AND COCAINE ADDICTION. 2012 8 856 26 CHROMATIN ACCESSIBILITY MAPPING OF THE STRIATUM IDENTIFIES TYROSINE KINASE FYN AS A THERAPEUTIC TARGET FOR HEROIN USE DISORDER. THE CURRENT OPIOID EPIDEMIC NECESSITATES A BETTER UNDERSTANDING OF HUMAN ADDICTION NEUROBIOLOGY TO DEVELOP EFFICACIOUS TREATMENT APPROACHES. HERE, WE PERFORM GENOME-WIDE ASSESSMENT OF CHROMATIN ACCESSIBILITY OF THE HUMAN STRIATUM IN HEROIN USERS AND MATCHED CONTROLS. OUR STUDY REVEALS DISTINCT NEURONAL AND NON-NEURONAL EPIGENETIC SIGNATURES, AND IDENTIFIES A LOCUS IN THE PROXIMITY OF THE GENE ENCODING TYROSINE KINASE FYN AS THE MOST AFFECTED REGION IN NEURONS. FYN EXPRESSION, KINASE ACTIVITY AND THE PHOSPHORYLATION OF ITS TARGET TAU ARE INCREASED BY HEROIN USE IN THE POST-MORTEM HUMAN STRIATUM, AS WELL AS IN RATS TRAINED TO SELF-ADMINISTER HEROIN AND PRIMARY STRIATAL NEURONS TREATED WITH CHRONIC MORPHINE IN VITRO. PHARMACOLOGICAL OR GENETIC MANIPULATION OF FYN ACTIVITY SIGNIFICANTLY ATTENUATES HEROIN SELF-ADMINISTRATION AND RESPONDING FOR DRUG-PAIRED CUES IN RODENTS. OUR FINDINGS SUGGEST THAT STRIATAL FYN IS AN IMPORTANT DRIVER OF HEROIN-RELATED NEURODEGENERATIVE-LIKE PATHOLOGY AND DRUG-TAKING BEHAVIOR, MAKING FYN A PROMISING THERAPEUTIC TARGET FOR HEROIN USE DISORDER. 2020 9 1091 29 COGNITIVE ENHANCERS AS A TREATMENT FOR HEROIN RELAPSE AND ADDICTION. HEROIN ADDICTION IS A DISORDER THAT STEMS FROM MALADAPTIVE PLASTICITY WITHIN NEURAL CIRCUITS AND PRODUCES BROAD COGNITIVE DEFICITS. DESPITE CONSIDERABLE ADVANCES IN PSYCHOTHERAPY AND PHARMACOTHERAPY FOR HEROIN RELAPSE AND ADDICTION, EFFECTIVE TREATMENTS FOR HEROIN USE DISORDER ARE STILL LACKING. INCREASING PRECLINICAL EVIDENCE INDICATES THAT HEROIN SEEKING BEHAVIOR IS PERSISTENT AFTER WITHDRAWAL, WHILE COGNITIVE DYSFUNCTIONS ASSOCIATED WITH CHRONIC HEROIN USE ARE AN IMPORTANT CONTRIBUTING FACTOR TO RISK OF HEROIN RELAPSE AND ADDICTION. COGNITIVE ENHANCERS MAY BE USED TO STIMULATE TREATMENT SUCCESS AND ENHANCE TREATMENT EFFICACY. THE PURPOSE OF THIS REVIEW IS TO OUTLINE THE LITERATURE THAT DEMONSTRATES THE COGNITIVE DEFICITS DURING THE DEVELOPMENT OF HEROIN ADDICTION AND WITHDRAWAL PROCESS, AND SEVERAL FACTORS THAT UNDERLINE THE EFFICACY OF COGNITIVE ENHANCERS FOR HEROIN USE DISORDERS. THE REVIEW, THEN, EXAMINES THE POTENTIAL USE AND PHARMACOLOGICAL MECHANISMS OF COGNITIVE ENHANCERS THAT ACT ON CHOLINERGIC, GLUTAMATERGIC, DOPAMINERGIC OR ADRENERGIC PATHWAYS. IT ALSO EXAMINES THE EFFECTS OF COMPOUNDS THAT ALTER CREB SIGNALING AND EPIGENETIC MECHANISMS IN ANIMAL MODEL OF HEROIN RELAPSE. THE CURRENT BODY OF RESEARCH REVEALS THE NEW INSIGHTS INTO THE PHARMACOLOGICAL MECHANISMS UNDERLYING HEROIN ADDICTION AND HOLDS A SIGNIFICANT PROMISE FOR COGNITIVE ENHANCERS AS AN IMPROVED APPROACH TO TREAT HEROIN USE DISORDER IN A MORE EFFICIENT AND PERSISTENT WAY. 2019 10 4849 24 OPIOID-MEDIATED HIV-1 IMMUNOPATHOGENESIS. DESPITE THE ABILITY OF COMBINATION ANTIRETROVIRAL THERAPY TO DRAMATICALLY SUPPRESS VIREMIA, THE BRAIN CONTINUES TO BE A RESERVOIR OF HIV-1 LOW-LEVEL REPLICATION. ADDING FURTHER COMPLEXITY TO THIS IS THE COMORBIDITY OF DRUG ABUSE WITH HIV-1 ASSOCIATED NEUROCOGNITIVE DISORDERS AND NEUROHIV. AMONG SEVERAL ABUSED DRUGS, THE USE OF OPIATES IS HIGHLY PREVALENT IN HIV-1 INFECTED INDIVIDUALS, BOTH AS AN ABUSED DRUG AS WELL AS FOR PAIN MANAGEMENT. OPIOIDS AND THEIR RECEPTORS HAVE ATTAINED NOTABLE ATTENTION OWING TO THEIR ABILITY TO MODULATE IMMUNE FUNCTIONS, IN TURN, IMPACTING DISEASE PROGRESSION. VARIOUS CELL CULTURE, ANIMAL AND HUMAN STUDIES HAVE IMPLICATED THE ROLE OF OPIOIDS AND THEIR RECEPTORS IN MODULATING VIRAL REPLICATION AND VIRUS-MEDIATED PATHOLOGY BOTH POSITIVELY AND NEGATIVELY. FURTHER, THE COMBINATORIAL EFFECTS OF HIV-1/HIV-1 PROTEINS AND MORPHINE HAVE DEMONSTRATED ACTIVATION OF INFLAMMATORY SIGNALING IN THE HOST SYSTEM. HEREIN, WE SUMMARIZED THE CURRENT KNOWLEDGE ON THE ROLE OF OPIOIDS ON PERIPHERAL IMMUNOPATHOGENESIS, VIRAL IMMUNOPATHOGENESIS, EPIGENETIC PROFILES OF THE HOST AND VIRAL GENOME, NEUROPATHOGENESIS OF SIV/SHIV-INFECTED NON-HUMAN PRIMATES, BLOOD-BRAIN-BARRIER, HIV-1 VIRAL LATENCY, AND VIRAL REBOUND. OVERALL, THIS REVIEW PROVIDES RECENT INSIGHTS INTO THE ROLE OF OPIOIDS IN HIV-1 IMMUNOPATHOGENESIS. GRAPHICAL ABSTRACT. 2020 11 3246 26 HEPATITIS B VIRUS (HBV) INDUCES THE EXPRESSION OF INTERLEUKIN-8 THAT IN TURN REDUCES HBV SENSITIVITY TO INTERFERON-ALPHA. HIGH LEVELS OF SERUM INTERLEUKIN-8 (IL-8) HAVE BEEN DETECTED IN CHRONIC HEPATITIS B (CHB) PATIENTS DURING EPISODES OF HEPATITIS FLARES. WE INVESTIGATED WHETHER HEPATITIS B VIRUS (HBV) MAY DIRECTLY INDUCE IL-8 PRODUCTION AND WHETHER IL-8 MAY ANTAGONIZE INTERFERON-ALPHA (IFN-ALPHA) ANTIVIRAL ACTIVITY AGAINST HBV. WE SHOWED THAT CHB PATIENTS HAD SIGNIFICANTLY HIGHER IL-8 LEVELS BOTH IN SERUM AND IN LIVER TISSUE THAN CONTROLS. IN HBV-REPLICATING HEPG2 CELLS, IL-8 TRANSCRIPTION WAS SIGNIFICANTLY ACTIVATED. AP-1, C/EBP AND NF-KB TRANSCRIPTION FACTORS WERE CONCURRENTLY NECESSARY FOR MAXIMUM IL-8 INDUCTION. MOREOVER, HBX VIRAL PROTEIN WAS RECRUITED ONTO THE IL-8 PROMOTER AND THIS WAS PARALLELED BY IL8-BOUND HISTONE HYPERACETYLATION AND BY ACTIVE RECRUITMENT OF TRANSCRIPTIONAL COACTIVATORS. INHIBITION OF IL-8 INCREASES THE ANTIVIRAL ACTIVITY OF IFN-ALPHA AGAINST HBV. OUR RESULTS INDICATE THAT HBV ACTIVATES IL-8 GENE EXPRESSION BY TARGETING THE EPIGENETIC REGULATION OF THE IL-8 PROMOTER AND THAT IL-8 MAY CONTRIBUTE TO REDUCE HBV SENSITIVITY TO IFN-ALPHA. 2013 12 2841 38 FREQUENCY OF THE DOPAMINE RECEPTOR D3 (RS6280) VS. OPIOID RECEPTOR MICRO1 (RS1799971) POLYMORPHIC RISK ALLELES IN PATIENTS WITH OPIOID USE DISORDER: A PREPONDERANCE OF DOPAMINERGIC MECHANISMS? WHILE OPIOIDS ARE A POWERFUL CLASS OF DRUGS THAT INHIBIT TRANSMISSION OF PAIN SIGNALS, THEIR USE IS TARNISHED BY THE CURRENT EPIDEMIC OF OPIOID USE DISORDER (OUD) AND OVERDOSE DEATHS. NOTWITHSTANDING PUBLISHED REPORTS, THERE REMAIN GAPS IN OUR KNOWLEDGE OF OPIOID RECEPTOR MECHANISMS AND THEIR ROLE IN OPIOID SEEKING BEHAVIOR. THUS, NOVEL INSIGHTS INTO MOLECULAR, NEUROGENETIC AND NEUROPHARMACOLOGICAL BASES OF OUD ARE NEEDED. WE PROPOSE THAT AN ADDICTIVE ENDOPHENOTYPE MAY NOT BE ENTIRELY SPECIFIC TO THE DRUG OF CHOICE BUT RATHER MAY BE GENERALIZABLE TO ALTERED BRAIN REWARD CIRCUITS IMPACTING NET MESOCORTICOLIMBIC DOPAMINE RELEASE. WE SUGGEST THAT GENETIC OR EPIGENETIC ALTERATIONS ACROSS DOPAMINERGIC REWARD SYSTEMS LEAD TO UNCONTROLLABLE SELF-ADMINISTRATION OF OPIOIDS AND OTHER DRUGS. FOR INSTANCE, DIMINISHED AVAILABILITY VIA KNOCKOUT OF DOPAMINE D3 RECEPTOR (DRD3) INCREASES VULNERABILITY TO OPIOIDS. BUILDING UPON THIS CONCEPT VIA THE USE OF A SOPHISTICATED POLYMORPHIC RISK ANALYSIS IN A HUMAN COHORT OF CHRONIC OPIOID USERS, WE FOUND EVIDENCE FOR A HIGHER FREQUENCY OF POLYMORPHIC DRD3 RISK ALLELE (RS6280) THAN OPIOID RECEPTOR MICRO1 (RS1799971). IN CONCLUSION, WHILE OPIOIDERGIC MECHANISMS ARE INVOLVED IN OUD, DOPAMINE-RELATED RECEPTORS MAY HAVE PRIMARY INFLUENCE ON OPIOID-SEEKING BEHAVIOR IN AFRICAN AMERICANS. THESE FINDINGS SUGGEST OUD-TARGETED NOVEL AND IMPROVED NEUROPHARMACOLOGICAL THERAPIES MAY REQUIRE FOCUS ON DRD3-MEDIATED REGULATION OF DOPAMINERGIC HOMEOSTASIS. 2022 13 5776 21 SPHN - THE SWISS AGING CITIZEN REFERENCE (SACR). IN SWITZERLAND BY 2045, WE EXPECT 2.7 MIO CITIZENS AGED 65+ OF WHOM 1.0 MIO. AGED 80+. A PRIORITY AND FOCUS OF PERSONALIZED HEALTH RESEARCH IS THEREFORE AGING BIOLOGY TO EXTEND HEALTHY LIFE EXPECTANCY. NOVEL MOLECULAR AND IMAGING FEATURES WILL EMERGE AS CANDIDATE TARGETS FOR RISK PREDICTION AND SCREENING OF CHRONIC DISEASES. IT IS OF UTMOST IMPORTANCE TO TEST THE CLINICAL AND PUBLIC HEALTH UTILITY OF CANDIDATE BIOMARKERS EVOLVING FROM THIS RESEARCH IN CITIZEN REFERENCE COHORTS. WE WILL BUILD A SWISS AGING CITIZEN REFERENCE (SACR), A TESTABLE AND SCALABLE REFERENCE COHORT OFFERING INTEROPERABLE, SEARCHABLE, AND ACCESSIBLE DATA. 1000 PARTICIPANTS FROM EXISTING SWISS CITIZEN COHORTS WILL BE COMBINED AND ANALYZED FOR DNA METHYLATION AND MRI BRAIN IMAGING. SACR WILL SERVE AS A TESTBED FOR CLINICAL AND PUBLIC HEALTH UTILITY OF CANDIDATE BIOMARKERS. AS FOR A PROOF-OF-CONCEPT STUDY, WE WILL CONDUCT AN AGNOSTIC SEARCH FOR STRUCTURAL AND FUNCTIONAL BRAIN FEATURES ASSOCIATED WITH EPIGENETIC AGING ACCELERATION TO EXAMINE THE POTENTIAL OF EPIGENETIC AGE ACCELERATION AS THE INTERMEDIATE AGING BIOMARKER AND TO BETTER UNDERSTAND THE AGING MECHANISM IN BRAIN. 2020 14 1088 31 COCAINE DIRECTLY IMPAIRS MEMORY EXTINCTION AND ALTERS BRAIN DNA METHYLATION DYNAMICS IN HONEY BEES. DRUG ADDICTION IS A CHRONIC RELAPSING BEHAVIORAL DISORDER. THE HIGH RELAPSE RATE HAS OFTEN BEEN ATTRIBUTED TO THE PERSEVERANCE OF DRUG-ASSOCIATED MEMORIES DUE TO HIGH INCENTIVE SALIENCE OF STIMULI LEARNT UNDER THE INFLUENCE OF DRUGS. DRUG ADDICTION HAS ALSO BEEN INTERPRETED AS A MEMORY DISORDER SINCE DRUG ASSOCIATED MEMORIES ARE UNUSUALLY ENDURING AND SOME DRUGS, SUCH AS COCAINE, INTERFERE WITH NEUROEPIGENETIC MACHINERY KNOWN TO BE INVOLVED IN MEMORY PROCESSING. HERE WE USED THE HONEY BEE (AN ESTABLISHED INVERTEBRATE MODEL FOR EPIGENOMICS AND BEHAVIORAL STUDIES) TO EXAMINE WHETHER OR NOT COCAINE AFFECTS MEMORY PROCESSING INDEPENDENTLY OF ITS EFFECT ON INCENTIVE SALIENCE. USING THE PROBOSCIS EXTENSION REFLEX TRAINING PARADIGM WE FOUND THAT COCAINE STRONGLY IMPAIRS CONSOLIDATION OF EXTINCTION MEMORY. BASED ON CORRELATION BETWEEN THE OBSERVED EFFECT OF COCAINE ON LEARNING AND EXPRESSION OF EPIGENETIC PROCESSES, WE PROPOSE THAT COCAINE INTERFERES WITH MEMORY PROCESSING INDEPENDENTLY OF INCENTIVE SALIENCE BY DIRECTLY ALTERING DNA METHYLATION DYNAMICS. OUR FINDINGS EMPHASIZE THE IMPACT OF COCAINE ON MEMORY SYSTEMS, WITH RELEVANCE FOR UNDERSTANDING HOW COCAINE CAN HAVE SUCH AN ENDURING IMPACT ON BEHAVIOR. 2018 15 3281 22 HETEROGENEOUS TFH CELL POPULATIONS THAT DEVELOP DURING ENTERIC HELMINTH INFECTION PREDICT THE QUALITY OF TYPE 2 PROTECTIVE RESPONSE. T FOLLICULAR HELPER (TFH) CELLS ARE AN IMPORTANT COMPONENT OF GERMINAL CENTER (GC)-MEDIATED HUMORAL IMMUNITY. YET, HOW A CHRONIC TYPE 1 VERSUS PROTECTIVE TYPE 2 HELMINTH INFECTION MODULATES TFH-GC RESPONSES REMAINS POORLY UNDERSTOOD. HERE, WE EMPLOY THE HELMINTH TRICHURIS MURIS MODEL AND DEMONSTRATE THAT TFH CELL PHENOTYPES AND GC ARE DIFFERENTIALLY REGULATED IN ACUTE VERSUS CHRONIC INFECTION. THE LATTER FAILED TO INDUCE TFH-GC B CELL RESPONSES, WITH TFH CELLS EXPRESSING TAU-BET AND INTERFERON-GAMMA. IN CONTRAST, INTERLEUKIN-4-PRODUCING TFH CELLS DOMINATE RESPONSES TO AN ACUTE, RESOLVING INFECTION. HEIGHTENED EXPRESSION AND INCREASED CHROMATIN ACCESSIBILITY OF T HELPER (TH)1- AND TH2 CELL-ASSOCIATED GENES ARE OBSERVED IN CHRONIC AND ACUTE INDUCED TFH CELLS, RESPECTIVELY. BLOCKADE OF THE TH1 CELL RESPONSE BY T-CELL-INTRINSIC T-BET DELETION PROMOTED TFH CELL EXPANSION DURING CHRONIC INFECTION, POINTING TO A CORRELATION BETWEEN A ROBUST TFH CELL RESPONSE AND PROTECTIVE IMMUNITY TO PARASITES. FINALLY, BLOCKADE OF TFH-GC INTERACTIONS IMPAIRED TYPE 2 IMMUNITY, REVEALING THE CRITICAL PROTECTIVE ROLE OF GC-DEPENDENT TH2-LIKE TFH CELL RESPONSES DURING ACUTE INFECTION. COLLECTIVELY, THESE RESULTS PROVIDE NEW INSIGHTS INTO THE PROTECTIVE ROLES OF TFH-GC RESPONSES AND IDENTIFY DISTINCT TRANSCRIPTIONAL AND EPIGENETIC FEATURES OF TFH CELLS THAT EMERGE DURING RESOLVING OR CHRONIC T. MURIS INFECTION. 2023 16 2328 27 EPIGENETIC REGULATION OF IMMEDIATE-EARLY GENE NR4A2/NURR1 IN THE MEDIAL HABENULA DURING REINSTATEMENT OF COCAINE-ASSOCIATED BEHAVIOR. PROPENSITY TO RELAPSE FOLLOWING LONG PERIODS OF ABSTINENCE IS A KEY FEATURE OF SUBSTANCE USE DISORDER. DRUGS OF ABUSE, SUCH AS COCAINE, CAUSE LONG-TERM CHANGES IN THE NEURAL CIRCUITRY REGULATING REWARD, MOTIVATION, AND MEMORY PROCESSES THROUGH DYSREGULATION OF VARIOUS MOLECULAR MECHANISMS, INCLUDING EPIGENETIC REGULATION OF ACTIVITY-DEPENDENT GENE EXPRESSION. UNDERLYING DRUG-INDUCED CHANGES TO NEURAL CIRCUIT FUNCTION ARE THE MOLECULAR MECHANISMS REGULATING ACTIVITY-DEPENDENT GENE EXPRESSION. OF NOTE, HISTONE ACETYLTRANSFERASES AND HISTONE DEACETYLASES (HDACS), POWERFUL EPIGENETIC REGULATORS OF GENE EXPRESSION, ARE DYSREGULATED FOLLOWING BOTH ACUTE AND CHRONIC COCAINE EXPOSURE AND ARE LINKED TO COCAINE-INDUCED CHANGES IN NEURAL CIRCUIT FUNCTION. TO BETTER UNDERSTAND THE EFFECT OF DRUG-INDUCED CHANGES ON EPIGENETIC FUNCTION AND BEHAVIOR, WE INVESTIGATED HDAC3-MEDIATED REGULATION OF NR4A2/NURR1 IN THE MEDIAL HABENULA, AN UNDERSTUDIED PATHWAY IN COCAINE-ASSOCIATED BEHAVIORS. NR4A2, A TRANSCRIPTION FACTOR CRITICAL IN COCAINE-ASSOCIATED BEHAVIORS AND NECESSARY FOR MHB DEVELOPMENT, IS ENRICHED IN THE CHOLINERGIC CELL-POPULATION OF THE MHB; YET, THE ROLE OF NR4A2 WITHIN THE MHB IN THE ADULT BRAIN REMAINS ELUSIVE. HERE, WE EVALUATED WHETHER EPIGENETIC REGULATION OF NR4A2 IN THE MHB HAS A ROLE IN REINSTATEMENT OF COCAINE-ASSOCIATED BEHAVIORS. WE FOUND THAT HDAC3 DISENGAGES FROM NR4A2 IN THE MHB IN RESPONSE TO COCAINE-PRIMED REINSTATEMENT. WHEREAS ENHANCING HDAC3 FUNCTION IN THE MHB HAD NO EFFECT ON REINSTATEMENT, WE FOUND, USING A DOMINANT-NEGATIVE SPLICE VARIANT (NURR2C), THAT LOSS OF NR4A2 FUNCTION IN THE MHB BLOCKED REINSTATEMENT BEHAVIORS. THESE RESULTS SHOW FOR THE FIRST TIME THAT REGULATION OF NR4A2 FUNCTION IN THE MHB IS CRITICAL IN RELAPSE-LIKE BEHAVIORS. 2019 17 2839 32 FOSB INDUCTION IN NUCLEUS ACCUMBENS BY COCAINE IS REGULATED BY E2F3A. THE TRANSCRIPTION FACTOR DELTAFOSB HAS BEEN PROPOSED AS A MOLECULAR SWITCH FOR THE TRANSITION FROM CASUAL, VOLITIONAL DRUG USE INTO A CHRONICALLY ADDICTED STATE, BUT THE UPSTREAM REGULATORY MECHANISMS GOVERNING DELTAFOSB EXPRESSION ARE INCOMPLETELY UNDERSTOOD. IN THIS STUDY, WE FIND A NOVEL REGULATORY ROLE FOR THE TRANSCRIPTION FACTOR E2F3, RECENTLY IMPLICATED IN TRANSCRIPTIONAL REGULATION BY COCAINE, IN CONTROLLING DELTAFOSB INDUCTION IN THE MOUSE NUCLEUS ACCUMBENS (NAC) FOLLOWING COCAINE ADMINISTRATION. WE FIND THAT AN E2F CONSENSUS SEQUENCE 500 BP UPSTREAM OF THE FOSB TRANSCRIPTION START SITE IS ENRICHED FOR E2F3 SPECIFICALLY OVER OTHER E2F ISOFORMS. WE FURTHER CONCLUDE THAT DELTAFOSB EXPRESSION IS REGULATED SPECIFICALLY BY E2F3A, NOT E2F3B, THAT E2F3A EXPRESSION IS SPECIFIC TO D1 RECEPTOR-EXPRESSING MEDIUM SPINY NEURONS, AND THAT E2F3A OVEREXPRESSION IN NAC RECAPITULATES THE INDUCTION OF FOSB AND DELTAFOSB MRNA EXPRESSION OBSERVED AFTER CHRONIC COCAINE EXPOSURE. E2F3A KNOCKDOWN IN NAC DOES NOT ABOLISH DELTAFOSB INDUCTION BY COCAINE, A RESULT CONSISTENT WITH PREVIOUSLY PUBLISHED DATA SHOWING THAT SINGULAR KNOCKDOWN OF UPSTREAM REGULATORS OF DELTAFOSB IS INSUFFICIENT TO BLOCK COCAINE-INDUCED EXPRESSION. FINALLY, TO ELUCIDATE POTENTIAL COMBINATORIAL EPIGENETIC MECHANISMS INVOLVED IN E2F3A'S REGULATION OF FOSB, WE EXPLORE H3K4ME3 ENRICHMENT AT THE FOSB PROMOTER AND FIND THAT IT IS NOT ENHANCED BY E2F3A OVEREXPRESSION, SUGGESTING THAT IT MAY INSTEAD BE A PRE-EXISTING PERMISSIVE MARK ALLOWING FOR E2F3A TO INTERACT WITH FOSB. TOGETHER, THESE FINDINGS SUPPORT A ROLE FOR E2F3A AS A NOVEL, UPSTREAM REGULATOR OF THE ADDICTION-MEDIATING TRANSCRIPTION FACTOR DELTAFOSB IN NAC. 2019 18 1327 26 DEPRESSION AND ANTIDEPRESSANTS: INSIGHTS FROM KNOCKOUT OF DOPAMINE, SEROTONIN OR NORADRENALINE RE-UPTAKE TRANSPORTERS. MAJOR DEPRESSIVE DISORDER (MDD) WHICH IS SUPPOSED TO RESULT FROM A COMPLEX INTERACTION OF GENETIC AND EPIGENETIC, ENVIRONMENTAL AND DEVELOPMENTAL FACTORS IS ONE OF THE MOST COMMON DEBILITATING PUBLIC HEALTH PROBLEMS. THE MOLECULAR MECHANISMS UNDERLYING THIS DISEASE ARE STILL LARGELY UNCLEAR. IDENTIFYING COMMON PATHWAYS FOR DIVERSE ANTIDEPRESSANTS (ADS) AS WELL AS NEW DRUG TARGETS AND THEREBY DEVELOPING MORE EFFECTIVE TREATMENTS ARE PRIMARY GOALS OF RESEARCH IN THIS FIELD. MAJOR TARGETS OF ADS ARE THE SEROTONIN TRANSPORTER (SERT), THE NORADRENALINE TRANSPORTER (NAT) AND ALSO THE DOPAMINE TRANSPORTER (DAT) LOCATED IN THE PLASMA MEMBRANE OF CORRESPONDING NEURONS. THESE MONOAMINE TRANSPORTERS (MATS) ARE IMPORTANT REGULATORS OF THE EXTRACELLULAR NEUROTRANSMITTER CONCENTRATION. AMONG THE CLINICALLY IMPORTANT ADS ARE TRICYCLIC ADS (E.G. IMIPRAMINE), SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIS, E.G. FLUOXETINE), SELECTIVE NORADRENALINE (NA) RE-UPTAKE INHIBITORS (SNRIS, E.G. REBOXETINE) AND NAT/DAT INHIBITORS LIKE BUPROPION. THIS REVIEW IS FOCUSSING ON BRAIN CHANGES IN MONOAMINE NEUROTRANSMITTER SYSTEMS, DOWNSTREAM TARGETS OF MONOAMINERGIC NEUROTRANSMISSION AS WELL AS OF BEHAVIOURS OF MICE WITH A CONVENTIONAL KNOCKOUT (KO) OF EITHER THE SERT, DAT OR NAT. MAT KNOCKOUT INDUCES CHANGES IN BEHAVIOUR AND BRAIN NEUROCHEMISTRY. ALTHOUGH AT LEAST NATKO AND SERTKO MICE WERE EXPECTED TO SHOW A PHENOTYPE LIKE AD-TREATED WILD-TYPE MICE, THIS HOLDS TRUE ONLY FOR THE NATKO MICE WHEREAS SERTKO MICE SHOW AN ANXIETY-LIKE PHENOTYPE. CHRONIC SOCIAL OR RESTRAINT STRESS-INDUCED DEPRESSION-LIKE BEHAVIOUR AND CONCOMITANT CHANGES IN BRAIN NEUROTROPHINS ARE PREVENTED BY PHARMACOLOGICALLY DIVERSE ADS AND BY NATKO. THUS, NATKO MICE ARE AN INTERESTING TOOL TO INVESTIGATE THE MECHANISMS BEYOND MONOAMINES RESPONSIBLE FOR DEPRESSION AS WELL AS FOR AD ACTIONS. 2011 19 6209 25 THE INTERFERON-STIMULATED GENE TRIM22: A DOUBLE-EDGED SWORD IN HIV-1 INFECTION. INFECTION OF TARGET CELLS BY THE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) IS HAMPERED BY CONSTITUTIVELY EXPRESSED HOST CELL PROTEINS PREVENTING OR CURTAILING VIRUS REPLICATION AND THEREFORE DEFINED AS "RESTRICTION FACTORS". AMONG THEM, MEMBERS OF THE TRIPARTITE MOTIF (TRIM) FAMILY HAVE EMERGED AS IMPORTANT PLAYERS ENDOWED WITH BOTH ANTIVIRAL EFFECTS AND MODULATORY CAPACITY OF THE INNATE IMMUNE RESPONSE. TRIM5ALPHA AND TRIM19 (I.E. PROMYELOCYTIC LEUKEMIA, PML) ARE AMONG THE BEST-CHARACTERIZED FAMILY MEMBERS; HOWEVER, IN THIS REVIEW WE WILL FOCUS ON THE POTENTIAL ROLE OF ANOTHER FAMILY MEMBER, I.E. TRIM22, A FACTOR STRONGLY INDUCED BY INTERFERON STIMULATION, IN HIV INFECTION IN VIVO AND IN VITRO IN THE CONTEXT OF ITS BROADER ANTIVIRAL EFFECTS. WE WILL ALSO FOCUS ON THE POTENTIAL ROLE OF TRIM22 IN HIV-1-INFECTED INDIVIDUALS SPECULATING ON ITS DUAL ROLE IN CONTROLLING VIRUS REPLICATION AND MORE COMPLEX ROLE IN CHRONIC INFECTION. AT THE MOLECULAR LEVELS, WE WILL REVIEW THE EVIDENCE IN FAVOR OF A RELEVANT ROLE OF TRIM22 AS EPIGENETIC INHIBITOR OF HIV-1 TRANSCRIPTION ACTING BY PREVENTING THE BINDING OF THE HOST CELL TRANSCRIPTION FACTOR SP1 TO THE VIRAL PROMOTER. THESE EVIDENCES SUGGEST THAT TRIM22 SHOULD BE CONSIDERED A POTENTIAL NEW PLAYER IN EITHER THE ESTABLISHMENT OR MAINTENANCE OF HIV-1 RESERVOIRS OF LATENTLY INFECTED CELLS UNAFFECTED BY COMBINATION ANTIRETROVIRAL THERAPY. 2018 20 6602 21 TWO KINDS OF TRANSCRIPTION FACTORS MEDIATE CHRONIC MORPHINE-INDUCED DECREASE IN MIR-105 IN MEDIAL PREFRONTAL CORTEX OF RATS. CHRONIC MORPHINE ADMINISTRATION ALTERS GENE EXPRESSION IN DIFFERENT BRAIN REGIONS, AN EFFECT WHICH MAY CONTRIBUTE TO PLASTIC CHANGES ASSOCIATED WITH ADDICTIVE BEHAVIOR. THIS CHANGE IN GENE EXPRESSION IS MOST POSSIBLY MEDIATED BY ADDICTIVE DRUG-INDUCED EPIGENETIC REMODELING OF GENE EXPRESSION PROGRAMS. OUR PREVIOUS STUDIES SHOWED THAT CHRONIC MORPHINE-INDUCED DECREASE OF MIR-105 IN THE MEDIAL PREFRONTAL CORTEX (MPFC) CONTRIBUTED TO CONTEXT-INDUCED RETRIEVAL OF MORPHINE WITHDRAWAL MEMORY. HOWEVER, HOW CHRONIC MORPHINE TREATMENT DECREASES MIR-105 IN THE MPFC STILL REMAINS UNKNOWN. THE PRESENT STUDY SHOWS THAT CHRONIC MORPHINE INDUCES ADDICTION-RELATED CHANGE IN MIR-105 IN THE MPFC VIA TWO KINDS OF TRANSCRIPTION FACTORS: THE FIRST TRANSCRIPTION FACTOR IS CREB ACTIVATED BY MU RECEPTORS-ERK-P90RSK SIGNALING PATHWAY AND THE SECOND TRANSCRIPTION FACTOR IS GLUCOCORTICOID RECEPTOR (GR), WHICH AS A NEGATIVE TRANSCRIPTION FACTOR, MEDIATES CHRONIC MORPHINE-INDUCED DECREASE IN MIR-105 IN THE MPFC OF RATS. 2022